Catamaran Bio

02.24.22 || Immuno-Oncology 360 || Using NK Cells to Fight Solid Tumors and Catalyze the Immune System

04.11.23 || Catamaran Bio Announces Preclinical Data from Allogeneic CAR-NK Cell Therapy Pipeline for Solid Tumors to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023

Catamaran is seeking an experienced, hands-on Research Associate / Senior Research Associate to support Catamaran’s development of an allogeneic NK cell drug product.

Catamaran seeks a research associate or senior research associate to run cell-based assays for its immune cell therapies. The role focuses on product characterization and assays supporting process development.

Caroline is a principal with Lightstone Ventures based out of the firm’s Dublin office.

Dominic joined Catamaran as Senior Director, In Vivo Pharmacology in March 2021. Prior to joining Catamaran, Dominic led the in vivo pharmacology teams at Cobalt Biomedicine and subsequently Sana Biotechnology.

Houman is a Managing Partner at SV Health Investors based out of their London offices and has founded seven SV companies.

Kevin is a Venture Partner at SV Health Investors and President and CEO of Enara Bio.

Looking to realize the full potential of cell therapy by powering a key type of immune cell, Natural Killer (NK) cells, with new properties to create transformative cancer treatments for more patients.

451 D Street Boston, MA 02210 catamaranhr@catamaranbio.com

Catamaran uses NK cells, synthetic biology, and non-viral cell engineering to create CAR-NK cell therapies.

Catamaran operates the site to provide information about the company. Its privacy policy covers information, including personally identifiable information.